DTx West 2024 | GreyGreen | 21 February 2024 | W Hollywood, 6250 Hollywood Blvd, Hollywood, CA 90028, USA

If we collectively ignite innovation, foster collaboration across disciplines, and prioritize patients at every turn, the digital therapeutics landscape will evolve into a hub of groundbreaking advancements. By embracing these transformative principles, the industry can unlock new realms of creativity and efficiency, setting the stage for a paradigm shift as a result of our commitment to innovation, collaboration, and patient-centricity, we’ll witness the radical transformation of treatment paradigms. Digital therapeutics will revolutionize healthcare, delivering personalized interventions, maximizing patient adherence, and ultimately elevating treatment outcomes to unprecedented heights.

A transformed healthcare landscape that places emphasis on empowering lives. Digital therapeutics, rooted in patient data and cutting-edge technology, will not only treat ailments but reshape the entire healthcare experience. The ultimate goal is an evidence-driven, patient-centered approach that empowers individuals to lead healthier, more fulfilling lives.

Agenda topics include:
• A breakdown from the Digital Therapeutics Alliance into the current state of DTx in 2024
• What valuable insights can we learn from the market’s performance in the past year?
• How is the DTA working to improve access to digital therapeutics in healthcare?
• Hear from the lobbyists
• Explore the US government’s perspective on digital therapeutics and its potential impact on the nation’s healthcare landscape. What’s the government’s vision?
• What is the access to prescription digital therapeutics bill and what does this mean for the DTx industry?
• What measures are being taken to regulate the DTx space while promoting innovation and patient safety?
• How can stakeholders collaborate to ensure that digital therapeutics are seamlessly integrated into existing healthcare systems, placing patient needs at the forefront?
• What are the key challenges and opportunities for regulatory bodies in adapting to the rapid advancements in digital therapeutics?
• How can payers, innovators, and pharmaceutical companies work together to create equitable access to digital therapeutics?
• How can stakeholders collaboratively gather, analyze, and leverage real-world data to establish the efficacy, safety, and long-term benefits of digital therapeutics in diverse patient populations?
• What is it going to take from each element of the industry to break DTx into the mainstream? What can you do better?
• What are the key strategies for establishing credibility and trust?
• How can digital therapeutics companies effectively find and engage patients for better outcomes?
• How do you define and target your ideal patient demographic?
• What are some examples of successful marketing strategies and what is it that sets them apart?
• How can we ensure strong evidence of effectiveness for diverse digital therapeutics in real-world settings?
• What novel methods validate the lasting impact of evidence-based digital therapeutics on behavior and outcomes?
• How do we maintain rigorous evidence standards while enabling agile development of patient-centered digital therapeutics?

2024 Speakers

MODERATORS:

Danny Kim
Head of WELT USA

Jessica Lake
Director of Scientific Affairs, Big Health

Adam Kaufman
Interim Project Lead – Marketplace, Mayo Clinic Platform, Mayo Clinic

Benjamin Alouf
Former Chief Medical Officer, Formerly Limbix

SPEAKERS:

Julie Fishman
Executive Director, Commercial Head (Global), Rx Business Accelerator, Astellas Pharma

Gautam Shah
Chief Product Officer, Carelon, Elevance Health

Ramita Tandon
Chief Clinical Trials Officer, Walgreens

Davide Ricci
US Vice President, SaMD, Novo Nordisk

Juhee Cho
Professor, Samsung Medical Center

Athena Robinson
Chief Clinical Officer, Woebot Health

Bray Patrick-lake
Senior Digital Health Specialist, Digital Health Center of Excellence, FDA

John Drakenberg
CEO & Founder, Alex Therapeutics

Yuma Nishikawa
Venture Capitalist, DG Daiwa Ventures

Ben Cox
Head of Digital Health, Team Consulting

Hillel Lehmann
Vice President, Transformation, Nestle Health Science

Samuel Ridout
Director of Research, Kaiser Permanente

Amy Edgar
Founder & Innovator, Children’s Integrated Center for Success

Brian Harris
Co-Founder & CEO, MedRhythms

Krista Russel
Head of Digital Health Solutions, Takeda

Kathryn Drzewiecki
Policy Advisor, Center for Devices & Radiological Devices, FDA

Tony Simon
VP of Cognitive Science, Akili Interactive

Kimberley Ferguson
Global Head of Commercial Partnerships in Personalized Healthcare, Roche

Andreas Caduff
Health Tech, Amazon

Jenna Tregarthen
Co-Founder & CEO, Bright Therapeutics

Doug Foster
Partner, Advanced Data Sciences

Ahmad Fayyad
Investment Associate, Hikma Pharmaceuticals

Ricky Choi
Head of Digital Health, Samsung

Andrea PIsa
Senior Human Factors Consultant, Team Consulting

Andy Molnar
Chief Executive Officer, Digital Therapeutics Alliance

Renae Beaumont
Assistant Professor of Psychology in Clinical Psychiatry, Weill Cornell Medicine

Kevin Brennan
Principal, Bluebird Strategies

Joe Perekupka
Chief Executive Officer, Freespira

Jason Parent
Director, Clinical Innovation, Point32Health

Doug Lee
VP, Business Development & Licensing | Global Head Digital & Data Science, Bayer

Michelle Russel
Senior Director, Client Success, Freespira

Simon Thomas
President, Freespira

Athena Robinson
Chief Clinical Officer, Woebot Health

Mike Rosenbluth
Chief Executive Officer, Swing Therapeutics

Linda Li
Partner, Cleveland Clinic

David Kim
Managing Director, DigiTx Partners

Daniel Emina
Associate Medical Director, Amen Clinics, Inc.

Sabrina Braham
Assistant Clinical Professor, Pediatrics, Stanford University School of Medicine

Jordan Silberman
Director of Clinical Analytics and Research, Office of Med Policy & Tech Assessment, Elevance Health

Herk Confer
VP Partnerships, UHG Strategy & Innovation, UnitedHealth Group

Timothy Law
Chief Medical Officer, Highmark

Dawn Gotkiewicz
Pediatrician, UPMC Children's Community Pediatrics

Daniel McCaffrey
VP Digital Health, Omron

John Drakenberg
Co-Founder & CEO, Alex Therapeutics

Matt Omernick
Co-Founder & Former Chief Creative Officer, Advisor, Formerly Akili Interactive

Angel Enrique
Senior Digital Health Scientist, Amwell

Adam Haim
Chief - Treatment and Preventive Intervention Research Branch, National Institute for Mental Health

Mette Dyhrberg
Founder & CEO, Mymee

Laura Taraboanta
Director, Medical Operations & Strategy, Click Therapeutics

Bob Cuyler
Chief Clinical Officer, Freespira

Alicia Kaplan
Medical Director Center Adult Anxiety, Allegheny Health Network

Daniel Duffy
Senior Digital Health Scientist, Amwell

Frank Karbe
Chief Executive Officer, Better Therapeutics

Aradhana Goel
Head of Product Design & Behavior Science, Digital Health Portfolio, Bayer

Adam Colborn
Director of Government Affairs, AMCP

Todd Farchione
Director of Unified Protocol Research Programs & Associate Professor, Boston University

Nayan Ghosh
Head of Commercial & Regulatory Strategy, Arcade Therapeutics

Andrzej Jonczyk
Co-Founder & US CEO, Prosoma

Acacia Parks
Founder, Liquid Amber

2024 Partners

KNOWLEDGE PARTNERS:
• Glooko
• Team
• Luminopia

SUMMIT PARTNERS:
• Dawn Health
• ADS
• DTxCC
• hattrick
• Definitive Healthcare

SUPPORTER:
• Lark